A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 483 participants.

Also called NCT05445895

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 483 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05445895
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05445895. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-16 (actual); primary completion 2025-10-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
Intervention (Drug)
Renexin CR 200/160mg
Intervention (Drug)
Plavix 75mg
Lead sponsor
SK Chemicals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05445895
Content hash
17102a1ea7e568109f54f37508c486ff6412ef01dc15a33bc790458b5cbe25bb